Regenxbio (RGNX)

• Market cap: $334M
• 1 day: -5.59%
• 5 days: -17.58%
• 1 month: 14.02%
• 3 months: -14.12%
• 6 months: -33.89%
• Year to date: -14.12%
• 1 year: -68.65%
• 5 years: -76.84%
• 10 years: -77.83%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Employees: 344

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

183% more call options, than puts

Call options by funds: $1.4M | Put options by funds: $494K

12% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 51

5% less funds holding

Funds holding: 186 [Q3] → 177 (-9) [Q4]

8.41% less ownership

Funds ownership: 93.37% [Q3] → 84.96% (-8.41%) [Q4]

11% less first-time investments, than exits

New positions opened: 39 | Existing positions closed: 44

33% less capital invested

Capital invested by funds: $484M [Q3] → $325M (-$159M) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $14 107% upside
• Avg. target: $31 364% upside
• High target: $52 670% upside

6 analyst ratings

• positive: 5 83%
• neutral: 1 17%
• negative: 0 0%

HC Wainwright & Co. Yi Chen 38% 1-year accuracy 63 / 167 met price target	404% upside $34	Buy Reiterated	21 Mar 2025
Chardan Capital Daniil Gataulin 27% 1-year accuracy 12 / 45 met price target	670% upside $52	Buy Maintained	20 Mar 2025
HC Wainwright & Co. Raghuram Selvaraju 34% 1-year accuracy 117 / 342 met price target	404% upside $34	Buy Maintained	17 Mar 2025
Morgan Stanley Judah Frommer 36% 1-year accuracy 4 / 11 met price target	256% upside $24	Overweight Maintained	14 Mar 2025
Goldman Sachs Paul Choi 50% 1-year accuracy 5 / 10 met price target	107% upside $14	Neutral Downgraded	11 Feb 2025